Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) — Noema Pharma, a clinical-stage biotech company targeting…
Year: 2022
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor…
SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meeting
BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) — SOTIO Biotech, a clinical…
Sofwave™ Granted U.S. Patent Covering Key Elements of the Company’s Proprietary SUPERB™ Non-Surgical Skin and Collagen Remodeling Technology
The patent protects key features of SUPERB’s ultrasound applicator and cooling technology. First U.S. patent…
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu…
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid Tumors WILMINGTON, Del., Oct….
TOWER ONE WIRELESS ANNOUNCES THIRTEEN TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $ 2,300,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF SEPTEMBER 2022 VANCOUVER, BC, CANADA, Oct. 18,…
Drs. Roger B. Cohen, Lee M. Ellis and John L. Marshall Join Actuate Therapeutics’ Scientific Advisory Board
CHICAGO and FORT WORTH, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc., a…
UPDATE — Accelus Announces Global Expansion of its FlareHawk Interbody Fusion System
Surgeons in 21 Countries Can Now Take Advantage of FlareHawk’s Minimal Insertion Profile, Multiplanar and…
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023…
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
Avicenna Academy Avicenna Academy The education portal provides modules, case studies and other resources related…
AnPac Bio Announces Plan to Implement ADS Ratio Change
PHILADELPHIA, Oct. 18, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac…
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for…
BioCryst to Report Third Quarter 2022 Financial Results on November 1
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox
PRESS RELEASE Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and…
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability,…
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of…
MediWound’s EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted YAVNE, Israel, Oct. 18,…
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
• ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor…